Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Avidity Biosciences, Inc. Director's Dealing 2020

Jun 17, 2020

30894_dirs_2020-06-16_dbd77dab-a0b6-463f-9a2b-4eb6277a5d70.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2020-06-16

Reporting Person: ELI LILLY & Co (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-06-16 Common Stock C 2169396 Acquired 2169396 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-06-16 Series C Preferred Stock $ C 4576342 Disposed Common Stock (2169396) Direct

Footnotes

F1: The shares of the Issuer's Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering.